01/25/2023 | Press release | Distributed by Public on 01/25/2023 05:09
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2023
Calithera Biosciences, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
343 Oyster Point Blvd.Suite 200
South San Francisco, California
|(Address of principal executive offices)||(Zip Code)|
Registrant's telephone number, including area code: (650)870-1000
Check the appropriate box below if the Form 8-Kfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12under the Exchange Act (17 CFR 240.14a-12)
Pre-commencementcommunications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencementcommunications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name of Each Exchange
on which Registered
|Common Stock, $0.0001 par value||CALA||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On January 9, 2023, Calithera Biosciences, Inc. announced that our Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval. We also announced, that in order to reduce costs and in connection with the planned dissolution, we were discontinuing all clinical development programs and reducing our workforce, including the termination of most employees by the end of the first quarter.
In light of our planned dissolution, on January 24, 2023, we received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising us that based upon Nasdaq's review and pursuant to Listing Rule 5101, Nasdaq believes that we are a "public shell," and that the continued listing of our securities is no longer warranted. We will not appeal Nasdaq's determination. Therefore, we expect, based on Nasdaq's written notice, that the trading of our common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSEwith the Securities and Exchange Commission, which will remove our common stock from listing and registration on Nasdaq.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CALITHERA BIOSCIENCES, INC.|
|Dated: January 25, 2023|
/S/ SUSAN M. MOLINEAUX, PH.D.
|Susan M. Molineaux, Ph.D.|
|President and Chief Executive Officer|